Track LB Pharmaceuticals Inc Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

LB Pharmaceuticals Inc Common Stock LBRX · Stock Open LB Pharmaceuticals Inc Common Stock in new tab

43.01 USD
EPS
-1.12
P/B
3.32
ROE
-38.80
Target Price
58.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
EPS-1.12
Book Value12.94
Price to Book3.32
Debt/Equity1.24
% Insiders0.920%
Estimates
Forward P/E-7.51
Forward EPS-5.73
Target Mean Price58.00

DCF valuation

Model fair value for LB Pharmaceuticals Inc Common Stock (LBRX)
Result
Sign in to run the valuation for LBRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 58.00 USD (low 35.00, high 80.00)
Low 35.00
Mean 58.00
High 80.00
Price 43.01
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

LB Pharmaceuticals Inc Common Stock Logo LB Pharmaceuticals Inc Common Stock Analysis (LBRX)

US Healthcare Official Website Stock

Is LB Pharmaceuticals Inc Common Stock a good investment? LB Pharmaceuticals Inc Common Stock (LBRX) is currently trading at 43.01 USD. Market analysts have a consensus price target of 58.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: LB Pharmaceuticals Inc Common Stock is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -5.73.

Investor FAQ

Does LB Pharmaceuticals Inc Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is LB Pharmaceuticals Inc Common Stock?

LB Pharmaceuticals Inc Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -1.12.

Company Profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Exchange Ticker
NASDAQ LBRX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion